每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析
DOI: 10.3971/j.issn.1000-8578.2016.05.017
Keywords: 2 Matched Case-control Investigation on Risk Factors of Gastric Cancer in Xianyou County,UGCG is Involved in Oxaliplatin Resistance Mechanism of Human Colon Cancer Through Regulating MDR1/P-gp Expression,Expression of CLIC4 in Gastric Carcinoma Tissues and Its Relevance to Microsatellite Instability,Periplocin Extracted from Cortex Periplocae(CPP) Induced Apoptosis of Gastric Cancer Cells MGC-803 Through Lysosomal Pathway,Gastric Cancer Mortality Trend and Difference Decomposition Analysis in Kunshan, Jiangsu Province, 1981-2014,Effect of Ubiquitin-like with PHD and Ring Finger Domain 1 on Invasion and Metastasis of Gastric Cancer and Related Mechanism,Effects of miR-711 on Invasion, Metastasis and Epithelial Mesenchymal Transition of Gastric Cancer Cells MGC-803,Clinical Efficacy and Toxicities of Oxaliplatin plus S-1(SOX) and Gemcitabine plus Cisplatin (GP) Regimens on Advanced Triple-negative Breast Cancer Patients,Relationship Between Lymphocyte Nadir and Radiotherapy Efficacy or Prognosis of Patients with Esophageal Carcinoma,Role of p53β Isoform in Inhibitory Effect of rmhTNF Combined with Cisplatin on Human Gastric Cancer Cell Growth,FOLFOX and FOLFOXIRI Regimens on Patients with Hepatic Metastasis from Colorectal Cancer after Operation
Abstract:
摘要 目的 比较每周脂质体紫杉醇联合替吉奥与奥沙利铂联合替吉奥一线治疗老年晚期胃癌的疗 效及安全性。方法 将119例老年晚期胃癌患者随机分为两组，A组62例患者采用每周脂质体紫杉醇联 合替吉奥方案，B组57例患者采用奥沙利铂联合替吉奥方案。比较两组患者的近期疗效、无疾病进展 时间（PFS）、总生存时间（OS）、体能状态和不良反应。结果 A组患者的客观缓解率（ORR）、 疾病控制率（DCR）、PFS、OS分别为22.0%、69.5%、6.4月和10.8月，B组分别为25.0%、67.9%、 6.4月和10.4月，两组间差异均无统计学意义（P均>0.05）。B组Ⅰ~Ⅱ级胃肠道反应、Ⅰ~Ⅱ级和Ⅲ~ Ⅳ级外周神经毒性发生率均较A组严重（P均<0.05）。结论 每周脂质体紫杉醇联合替吉奥治疗老年 晚期胃癌的近期疗效与传统的奥沙利铂联合替吉奥相似，但前者患者的耐受性更好，可推荐作为老年 晚期胃癌患者治疗的首要选择
Full-Text
